• Necrosulfonamide (SKU B7731): Reliable MLKL Inhibition in Ne

  2026-06-08

  This article addresses practical challenges in necroptosis assay design and data interpretation, demonstrating how Necrosulfonamide (SKU B7731) delivers reproducible, selective inhibition of MLKL-mediated cell death. Scenario-driven Q&A blocks illustrate workflow optimization, evidence-based protocol adjustments, and informed product selection, supporting robust cell death pathway research.

• EZ Cap Cy5 Firefly Luciferase mRNA: Precision in Dual-Mode T

  2026-06-08

  Explore how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) elevates mRNA delivery, dual-modality imaging, and translational efficiency. This article uniquely dissects practical assay decisions, referencing recent advances in mRNA lipoplex technology.

• Applied Workflows with JNJ-26481585 (Quisinostat) in Tumor R

  2026-06-07

  JNJ-26481585 (Quisinostat) offers robust, reproducible workflows for overcoming drug resistance and inducing apoptosis in diverse cancer models. Its precision against class I HDACs and proven ability to downregulate TRIM21 set it apart for advanced translational research.

• Cy5-UTP for High-Sensitivity RNA Labeling & FISH Workflows

  2026-06-06

  Cy5-UTP (Cyanine 5-UTP) enables direct, high-contrast RNA probe synthesis for fluorescence in situ hybridization (FISH) and dual-color arrays. Discover how its robust incorporation streamlines workflow, facilitates multiplexed detection, and empowers troubleshooting in advanced molecular biology applications.

• AG-120 (Ivosidenib): Applied Workflows for IDH1-Mutant AML R

  2026-06-05

  Unlock the power of AG-120 (Ivosidenib) for precise 2-hydroxyglutarate reduction and myeloid differentiation in IDH1-mutant acute myeloid leukemia. This guide details cutting-edge experimental protocols, troubleshooting tips, and strategic insights leveraging the latest discoveries in metabolic rewiring.

• Gly-Gly-Phe-Gly (GGFG) Peptide: Enabling Precise Drug Conjug

  2026-06-05

  Gly-Gly-Phe-Gly (GGFG) peptide unlocks next-gen bioconjugation by serving as a high-purity, flexible linker for antibody-drug conjugates and peptide engineering workflows. This article translates the latest experimental breakthroughs into actionable protocols and troubleshooting insights for researchers seeking to optimize drug delivery systems with GGFG.

• Cabozantinib (XL184): Multi-Target RTK Inhibition in Cancer

  2026-06-04

  Cabozantinib (XL184) is a potent, multi-kinase inhibitor validated in renal cell carcinoma and medullary thyroid cancer research. It precisely disrupts VEGFR2, MET, RET, and related RTK signaling, suppressing tumor proliferation and angiogenesis. Quantitative phosphoproteomics confirm robust, timescale-dependent signaling adaptations under both acute and chronic exposure.

• Heparin Sodium: Advanced Insights for Precision Anticoagulan

  2026-06-04

  Explore the multifaceted role of heparin sodium as a glycosaminoglycan anticoagulant in modern thrombosis and cell interaction studies. This article delivers deeper protocol guidance, cross-talk with nanovesicle research, and strategic context for APExBIO’s heparin sodium beyond standard assay workflows.

• Reactive Oxygen Species Assay Kit: Precision for Oxidative S

  2026-06-03

  Leverage the Reactive Oxygen Species Assay Kit (DHE) to quantitatively assess intracellular superoxide and decode the nuances of oxidative stress in living cells. With advanced protocol design and troubleshooting tips, this guide empowers researchers to optimize redox signaling, apoptosis, and immunotoxicity investigations with confidence.

• Belinostat (PXD101): Pan-HDAC Inhibition for Next-Gen Cancer

  2026-06-03

  This article examines how Belinostat (PXD101)—a potent, nanomolar-range pan-HDAC inhibitor—empowers translational researchers to dissect chromatin acetylation, alternative splicing, and cancer cell cycle control. By bridging mechanistic epigenetics with actionable laboratory strategy, we spotlight validated use in urothelial and prostate cancer models, integrate paradigm-shifting insights from spliceosome research in hepatocellular carcinoma, and map a forward path for combinatorial epigenetic cancer therapy.

• Cimetidine in Translational Research: From H2 Antagonism to

  2026-06-02

  Explore the mechanistic and strategic value of Cimetidine, a histamine-2 receptor antagonist with unique partial agonist activity, in advanced cancer and blood-brain barrier (BBB) research. This article bridges biological rationale, experimental protocols, and translational guidance, highlighting APExBIO's high-purity Cimetidine for cutting-edge laboratory workflows.

• Disrupting PD-L1 Recycling in Myeloid Cells Enhances T-cell

  2026-06-02

  This study introduces an anti-PD-L1 antibody (H1A) that induces PD-L1 degradation in myeloid cells, overcoming resistance mechanisms associated with PD-L1 recycling. The findings reveal improved tumor control and T-cell responses, suggesting a promising direction for next-generation immune checkpoint therapies.

• Spermine: Endogenous Polyamine for Ion Channel Modulation

  2026-06-01

  Spermine, an endogenous polyamine, is transforming ion channel modulation and cellular metabolism research with unmatched precision. Its role as a physiological blocker of inward rectifier potassium (K+) channels uniquely enables experiments probing membrane dynamics, excitability, and viral egress mechanisms.

• Mianserin Hydrochloride (SKU A1796): Data-Backed Lab Solutio

  2026-06-01

  This scenario-driven article offers evidence-based guidance for using Mianserin Hydrochloride (SKU A1796) in cell viability, cytotoxicity, and neuroscience assays. Drawing from controlled trials and validated product data, it addresses pain points in assay reproducibility, solubility, and supplier reliability, enabling researchers to make informed decisions and optimize experimental outcomes with APExBIO's compound.

• Capsazepine Targets MCL1 to Overcome Tamoxifen Resistance in

  2026-05-31

  This study identifies capsazepine as a novel MCL1 inhibitor that can reverse tamoxifen resistance in estrogen receptor-positive breast cancer. The findings provide a mechanistic rationale for targeting MCL1 and suggest new combined therapeutic strategies for overcoming endocrine therapy resistance.

401 records 12/27 page Previous Next First page 上5页 1112131415 下5页 Last page